Analysts Offer Insights on Healthcare Companies: Orchard Therapeutics (NASDAQ: ORTX) and Arbutus Biopharma (NASDAQ: ABUS)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Orchard Therapeutics (ORTXResearch Report) and Arbutus Biopharma (ABUSResearch Report).

Orchard Therapeutics (ORTX)

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Orchard Therapeutics yesterday and set a price target of $28.00. The company’s shares closed last Monday at $11.57.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 11.6% and a 65.0% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Springworks Therapeutics, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Orchard Therapeutics with a $26.50 average price target.

See today’s analyst top recommended stocks >>

Arbutus Biopharma (ABUS)

In a report released yesterday, Keay Nakae from Chardan Capital reiterated a Hold rating on Arbutus Biopharma, with a price target of $1.50. The company’s shares closed last Monday at $1.45, close to its 52-week low of $0.82.

According to TipRanks.com, Nakae is ranked 0 out of 5 stars with an average return of -7.2% and a 38.6% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Arrowhead Research, and Alnylam Pharma.

Arbutus Biopharma has an analyst consensus of Hold, with a price target consensus of $1.63.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.